Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
Mankind Pharma moved higher in a quarterly results development for Q2 FY27.
· BS Companies, Economic Times Markets, ET Stocks
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
Key facts
- Period
- Q2 FY27
The analysis
Mankind Pharma reported ₹4,338 crore for Q2 FY27, with movement of 37.7% and 17.3% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.9% on the day at ₹2,492.80, and has returned -3.2% over three months. It sits 5% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Mankind Pharma is running 2.3 points behind its peers.
For Mankind Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Mankind Pharma (MANKIND), in Pharma & Healthcare.
- Over three months: Mankind Pharma -3.2% against Pharma & Healthcare -0.9% (2.3 points behind).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Mankind PharmaMANKIND · Pharma & Healthcare | ₹2,492.80 | +0.9% | -0.4% | -3.2% | -4.8% | 1.0× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Mankind Pharma
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses
Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy